ライフサイエンスコーパス: advanced breast cancer

1 eviously treated patients with HER2-positive advanced breast cancer.

2 apy in patients with inflammatory or locally advanced breast cancer.

3 vant therapy for HER2-overexpressing locally advanced breast cancer.

4 apeutic approach to treat inoperable locally advanced breast cancer.

5 s for patients with locally and systemically advanced breast cancer.

6 hemotherapy in women with primary or locally advanced breast cancer.

7 epilone in women with metastatic and locally advanced breast cancer.

8 to doxorubicin-based chemotherapy in locally advanced breast cancer.

9 ion should be evaluated for the treatment of advanced breast cancer.

10 mal growth factor receptor 2 (HER2)-positive advanced breast cancer.

11 nducted a phase II study in 76 patients with advanced breast cancer.

12 nd are more likely to receive a diagnosis of advanced breast cancer.

13 tment of anthracycline- and taxane-resistant advanced breast cancer.

14 owth factor receptor 2 (HER2) overexpressing advanced breast cancer.

15 and/or poor-performance status patients with advanced breast cancer.

16 pically distinct from other forms of locally advanced breast cancer.

17 imal schedules of taxanes in early-stage and advanced breast cancer.

18 epidermal growth factor receptor 2-negative advanced breast cancer.

19 by prior aromatase inhibitor (AI) therapy in advanced breast cancer.

20 emotherapy response in patients with locally advanced breast cancer.

21 49 eligible randomised controlled trials of advanced breast cancer.

22 herapy compared with GM-CSF in patients with advanced breast cancer.

23 ndard therapy for estrogen receptor-positive advanced breast cancer.

24 Bone metastases are common in patients with advanced breast cancer.

25 of estrogen receptor-positive, HER2-negative advanced breast cancer.

26 with HER2-negative/hormone receptor-positive advanced breast cancer.

27 choice in patients with heavily pre-treated advanced breast cancer.

28 ne treatment for patients with HER2-positive advanced breast cancer.

29 metastases among patients with HER2-positive advanced breast cancer.

30 hormone receptor-positive and HER2-negative advanced breast cancer.

31 crine therapy for patients with HER-positive advanced breast cancer.

32 ug Administration (FDA) for the treatment of advanced breast cancer.

33 istant and taxane-pretreated, HER2-positive, advanced breast cancer.

34 first-line therapy in patients with AI-naive advanced breast cancer.

35 rexpressed in breast cancer, particularly in advanced breast cancer.

36 ation chemotherapy is commonly used to treat advanced breast cancer.

37 improved PFS in patients with HER2-negative advanced breast cancer.

38 e in women with BRCA1 or BRCA2 mutations and advanced breast cancer.

39 occurrence in the majority of patients with advanced breast cancer.

40 ptake and patterns of aggressive behavior in advanced breast cancer.

41 outcome for women with both early-stage and advanced breast cancer.

42 al growth factor receptor 2 (HER2) -positive advanced breast cancer.

43 ctomy for the treatment of early and locally advanced breast cancer.

44 chemotherapy on ECD levels, in patients with advanced breast cancer.

45 xel (GD) with capecitabine-docetaxel (CD) in advanced breast cancer.

46 combination in patients with ErbB2-positive advanced breast cancer.

47 n a phase II clinical trial in patients with advanced breast cancer.

48 axel (GT) versus paclitaxel in patients with advanced breast cancer.

49 mechanism of metastasis and hypercalcemia in advanced breast cancers.

50 n initial staging of inflammatory or locally advanced breast cancer?

51 In a previous trial in women with locally advanced breast cancer, 3 months of high-dose epirubicin

52 ars (range, 30 to 90 years); 32% had locally advanced breast cancer, 42% had been diagnosed with brea

53 ugh trastuzumab is approved for treatment of advanced breast cancer, a number of concerns exist with

54 with these Abs are approved for treatment of advanced breast cancer, a number of concerns exist.

55 versus letrozole (LET) in receptor-positive advanced breast cancer (ABC).

56 II study documents a role for gemcitabine in advanced breast cancer after anthracycline-based adjuvan

57 acy of this technique for patients with more advanced breast cancer after neoadjuvant chemotherapy.

58 ctometry was associated with reduced risk of advanced breast cancer among women with light constituti

59 hesis that sunlight exposure reduces risk of advanced breast cancer among women with light skin pigme

60 In women with advanced breast cancer and acquired resistance to aromat

61 llness were more likely to be diagnosed with advanced breast cancer and aggressive tumor characterist

62 One hundred ninety-one patients with locally advanced breast cancer and cytologically documented ALN

63 e occurred in all five patients with locally advanced breast cancer and in eight of 20 patients (40%;

64 e standard of care for patients with locally advanced breast cancer and is being evaluated in patient

65 hly active in women with HER2-overexpressing advanced breast cancer and is well tolerated.

66 usion, D1R overexpression is associated with advanced breast cancer and poor prognosis.

67 cause mortality, as well as the incidence of advanced breast cancer and treatment-related morbidity;

68 a suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and tre

69 orld region, number of previous regimens for advanced breast cancer, and presence of visceral disease

70 tients with previously treated HER2-positive advanced breast cancer, and validate HER2 as a therapeut

71 BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of loc

72 that 14-3-3 zeta is overexpressed in >40% of advanced breast cancers, and this overexpression predict

73 differences in approach to and management of advanced breast cancer; and (4) discuss treatment in ter

74 nonwhite ethnicity, be obese, and have more advanced breast cancer at diagnosis.

75 umab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free

76 ted the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression.

77 Resequencing in a multiethnic panel of 95 advanced breast cancer cases revealed no common missense

78 he EGFR is common in many cancers, including advanced breast cancer, characterization of EGF-induced

79 ain, Saudi Arabia, Oman, Qatar, and Kuwait), advanced breast cancer, colorectal cancer, leukaemia, th

80 niluracil has high activity in patients with advanced breast cancer comparable with the most active c

81 of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve impo

82 recommended for patients with HER2-positive advanced breast cancer, except for those with clinical c

83 ng everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progressi

84 ted from patients with metastatic or locally advanced breast cancer express high levels of the adipon

85 Advanced breast cancers frequently metastasize to bone,

86 iscriminating patients with stage II or more advanced breast cancers from healthy females had an area

87 R61 transcripts in tumors from patients with advanced breast cancer, further ratifying the clinical r

88 The LABC (locally advanced breast cancer) group included 17 patients with

89 PK pathway contributes to the maintenance of advanced breast cancers harboring Pten loss.

90 ase II and III trials of hormonal therapy in advanced breast cancer have examined the role of exemest

91 more high-risk alleles increases the risk of advanced breast cancer in a dose-response fashion.

92 49 tissue samples from patients with locally advanced breast cancer in a prospective study.

93 dered for use as an alternative treatment of advanced breast cancer in postmenopausal women after tre

94 graphy to characterize HA in mouse models of advanced breast cancer in relevant skeletal locations.

95 d limitations of serum ECD in both early and advanced breast cancer in the following clinical context

96 d demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II s

97 We found an increased risk of advanced breast cancer in women carrying an A2 allele.

98 EER) database suggests that the incidence of advanced breast cancer in young women is increasing.

99 buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the P

100 e other hand, Hsf1 expression increases with advanced breast cancer, indicating that there is an addi

101 Much of the morbidity of advanced breast cancer is a consequence of this process.

102 in as first-line chemotherapy for women with advanced breast cancer is an active regimen.

103 ave recently reported that increased risk of advanced breast cancer is associated with a common allel

104 of tamoxifen in the sequential strategy for advanced breast cancer is less well studied.

105 Improvements in the treatment of locally advanced breast cancer (LABC) are needed.

106 Locally advanced breast cancer (LABC) is commonly treated with n

107 Locally advanced breast cancer (LABC) is commonly treated with n

108 The prognosis of patients with locally advanced breast cancer (LABC) remains poor.

109 haracterize the biologic response of locally advanced breast cancer (LABC) to chemotherapy using (15)

110 inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to

111 he conventional primary treatment in locally advanced breast cancer (LABC).

112 prospectively to a second set of 20 locally advanced breast cancer lesions not included in the initi

113 opausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatme

114 An advanced breast cancer model was established by inoculat

115 Patients with advanced breast cancer often fail to respond to treatmen

116 treatment of naive hormone receptor-positive advanced breast cancer on the basis of an improvement in

117 Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/k

118 Patients with locally advanced breast cancer or MBC were treated with the arom

119 95% CI (confidence interval), 0.65-1.12] or advanced breast cancer (OR, 0.84; 95% CI, 0.54-1.32).

120 e first demonstrate that a majority of large advanced breast cancers overexpress translation regulato

121 effective in the treatment of patients with advanced breast cancer overexpressing or amplifying HER2

122 Our data show that advanced breast cancer patients have an increased propor

123 Advanced breast cancer patients were treated with ixabep

124 For 20 newly diagnosed, untreated, locally advanced breast cancer patients, both the maximum SUV an

125 al metastases, the leading cause of death in advanced breast cancer patients, depend on tumor cell in

126 ent of resistance to aromatase inhibitors in advanced breast cancer patients.

127 is may help eradicate this deadly feature in advanced breast cancer patients.

128 NK cell functions are profoundly altered in advanced breast cancer patients.

129 The safety profile was consistent with an advanced breast cancer population receiving systemic the

130 ears) with centrally confirmed HER2-positive advanced breast cancer previously treated with both tras

131 l in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroi

132 capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzum

133 ized trial, patients with metastatic/locally advanced breast cancer previously untreated for advanced

134 Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aro

135 stance, and its ultimate place in therapy of advanced breast cancer remains to be determined.

136 Patients with locally advanced breast cancer require multimodality treatment c

137 In patients with advanced breast cancer responsive to cytotoxic chemother

138 e a biomarker for the onset of ovulation and advanced breast cancer risk.

139 Sixteen women with biopsy-confirmed locally advanced breast cancer scheduled to undergo doxorubicin-

140 docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anth

141 ment option for postmenopausal patients with advanced breast cancer that has become refractory to sta

142 pecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatme

143 or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone rece

144 e sought to study in detail these aspects of advanced breast cancers that have resulted in lethal dis

145 Hypoxia is a common feature of locally advanced breast cancers that is associated with increase

146 mic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free

147 ghly expressed in both cancer cell lines and advanced breast cancer tissues, and the levels of TRIM28

148 n hematopoietic recovery in 88 patients with advanced breast cancer treated with high-dose chemothera

149 xtracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data

150 outcomes for a small number of patients with advanced breast cancer treated with weekly infusions of

151 astrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer) trial.

152 ograms/kg/d for 5 or 7 days in 38 women with advanced breast cancer undergoing high-dose chemotherapy

153 Thirty-nine patients with locally advanced breast cancer underwent (18)F-FDG PET before an

154 with estrogen receptor (ER)-positive locally advanced breast cancer was investigated by analyzing tum

155 Survival in advanced breast cancer was not affected by group therapy

156 of paclitaxel and cisplatin in patients with advanced breast cancer was performed to determine the ob

157 Advanced breast cancer was reduced for women aged 50 yea

158 rmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were assigned to two sequential c

159 nts with anthracycline- and taxane-resistant advanced breast cancer were enrolled onto this open-labe

160 ts that are now outdated, and definitions of advanced breast cancer were heterogeneous.

161 ber 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicente

162 with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuz

163 y-one patients with inflammatory and locally advanced breast cancer were treated with bevacizumab for

164 ohorts of three patients with ErbB2-positive advanced breast cancer were treated with escalating dose

165 Patients with inflammatory or locally advanced breast cancer were treated with one cycle of be

166 All locally advanced breast cancers were (18)F-fluciclovine-avid.

167 oprotective agent when used in patients with advanced breast cancer who continue to receive doxorubic

168 e status 0-2) with progressive HER2-positive advanced breast cancer who had received two or more HER2

169 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression

170 new standard for patients with HER2-positive advanced breast cancer who have previously received tras

171 n the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxife

172 wo FDG PET scans in 12 patients with locally advanced breast cancer who received G-CSF treatment were

173 Forty-one patients with advanced breast cancer who were either over the age of 6

174 t in patients with hormone receptor-positive advanced breast cancer who were not given dexamethasone

175 buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrin

176 Patients with advanced breast cancer who were treated with HDC without

177 andomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated

178 One hundred two women with advanced breast cancer, who were offered palliative chem

179 eatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamox

180 rative chemotherapy in patients with locally advanced breast cancer with better sensitivity for prima

181 on cost-effectiveness of liver resection for advanced breast cancer with liver metastasis are lacking

182 on cost-effectiveness of liver resection for advanced breast cancer with liver metastasis are lacking

183 erphase, and have low or no efficacy against advanced breast cancer with mutant or deficient p53.

184 r older, with locally assessed HER2-positive advanced breast cancer, with Eastern Cooperative Oncolog

185 ated into major advances in the treatment of advanced breast cancer, with several targeted therapies

186 ved previous trastuzumab or chemotherapy for advanced breast cancer within 12 months of randomisation